Narayana Hrudayalaya Ltd

Q2 FY26Healthcare Services

Narayana Hrudayalaya Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,816

Market cap₹38.9K Cr

P/E45.1

Updated23 Aug 2026

Read5 min read

The short version

Hospital patient flow in new hospitals is still establishing; initially, high minimum guarantees cause higher professional fees as a percentage of revenue, but this is expected to moderate over time, aligning with peers. EBITDA growth driven by volume pick-up through better payor-mix with more high-paying payors, not just pricing increases (low single-digit pricing hikes annually).

From Narayana Hrudayalaya Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Hospital patient flow in new hospitals is still establishing; initially, high minimum guarantees cause higher professional fees as a percentage of revenue, but this is expected to moderate over time, aligning with peers. (Page 25)
Volumes are currently stabilizing; from next two quarters onwards, positive volume growth alongside improved realizations due to better payor-mix is anticipated. (Page 15)
Incremental revenue growth is attributed to better paying payors, efficiency improvements, throughput enhancement, and increase in high-order procedures rather than pricing hikes. (Page 25)
Cayman hospital revenue saw significant growth post-commissioning of new hospital, with approximately 50% increase in discharges and outpatient/daycare volumes; further growth expected for a few more quarters before moderating to high single-digit growth. (Pages 4, 15)
Insurance business growth in Cayman is early-stage with strong sales pipeline and increasing employer interest, but underwriting results will stabilize only over multiple quarters; room for considerable growth remains. (Pages 12, 15)
India business is growing through optimization, payer-mix improvements, and patient opting for higher configuration beds, even without adding capacity; scope for continued growth before new beds come online. (Page 6)
Clinics and insurance businesses show positive momentum with declining losses; expected to improve in coming quarters with balanced growth and profitability. (Page 5)

Profitability & Margins

EBITDA growth driven by volume pick-up through better payor-mix with more high-paying payors, not just pricing increases (low single-digit pricing hikes annually).
Operational efficiencies and throughput improvements continue to support profit growth, including higher order procedures and niche work like robotic surgeries.
Cayman hospital revenue expected to stabilize after initial large jump post-new hospital commissioning; growth will moderate to high single digits after 2-3 quarters.
Insurance business in Cayman is early stage, growing rapidly with significant room to expand; breakeven/profit timing uncertain but losses are declining.
India business continues margin improvement via optimization, payer-mix, and increased realizations, even without adding beds.
Clinics and insurance segment losses are reducing, with a trend of improving profitability expected over coming years.
CapEx of INR 3000 crores planned over next 3 years in India for expansion, signaling future revenue and earnings growth potential.
Overall, sustainable earnings growth expected through volume, payer-mix, efficiency, and strategic expansion, though some moderation after initial scaling phases.

See what Narayana Hrudayalaya Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Planned CapEx guidance for FY26 and FY27: Detailed guidance for FY27 will be provided closer to year-end.
Over the next three years, a total of about INR 3,000 crores CapEx is planned in India, covering Greenfield, Brownfield, Operations & Maintenance, and acquisitions.
Spend breakup and project status for individual hospitals are available in the investor slides.
Some spillover of CapEx timing expected, with cash outflows possibly extending slightly beyond fiscal year boundaries.
Investments include setting up new hospitals (e.g., 100-bed hospital in Bangalore expected by Q1 FY26).
Strategic investments in robotic surgeries are ongoing, involving high upfront and operational costs initially, expected to break even or generate returns over time.
Investment in digital transformation and AI applications (e.g., software commercialization like Medha AI and Athma Health Tech) is also underway, albeit currently small-scale revenue-wise.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

No explicit mention of new fundraising through equity or additional debt in the near term.
Recent acquisition funded with GBP 40 million equity (from Cayman cash reserves) and GBP 150 million debt, serviced by the acquired entity.
Future capitalization plans include a 3-year investment plan of about INR 3000 crores in India covering Greenfield, Brownfield, O&M, and acquisitions; exact CapEx guidance for FY27 will be provided closer to year-end.
No clear indication of fresh fundraising for these investments; likely to be funded from internal accruals and existing resources.
Structured debt arrangements have been used for recent acquisitions to align repayments with target cash flows.
No mention of issuing equity to external investors to fund growth or acquisitions.

See what Narayana Hrudayalaya Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript and document do not contain specific information on the current or expected order book or pending orders for Narayana Hrudayalaya Limited. The discussions mainly focus on hospital operations, EBITDA growth, insurance business progress, acquisition financing, robotic surgeries, payor-mix improvements, and capacity utilization. Key points relevant to growth and capacity: - Volume and case-mix improvements are driving revenue growth. - New hospital commissioning contributes to increased patient volumes but patient flow is still stabilizing. - Optimization of payor-mix and pricing improvements are boosting margins. - Planned bed additions (e.g., 100 beds in Bangalore) are expected to commission in FY26 Q1. - Growth in EBITDA is driven more by volume and better payer-mix than pricing increases. No explicit mention of an order book or pending orders is found in the document.

Narayana Hrudayalaya Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.6K Cr, net profit ₹224 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Narayana Hrudaya's management said in earlier quarters

Others in Healthcare Services this season

Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
Dr Lal Pathlabs (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…
Health.Global (Q2 FY26)
Medium-term goal to realize Rs.4,000 crore revenue potential over 4-5 years from current Rs.2,200 crore at existing price points and optimized utilization. Key…

Compare:vs Apollo Hospitals vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Narayana Hrudayalaya Ltd Q2 FY26 results?

What is Narayana Hrudayalaya Ltd share price analysis?

Narayana Hrudayalaya Ltd currently shows a neutral. The stock trades at a P/E of 45.1 with a market cap of ₹38,892 Cr. Investors should review the full earnings analysis for detailed insights.

Is Narayana Hrudayalaya Ltd planning capital expenditure?

Planned CapEx guidance for FY26 and FY27: Detailed guidance for FY27 will be provided closer to year-end.

Keep Narayana Hrudayalaya Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.